This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds). All three drugs were administered for five consecutive days in induction and four consecutive days in consolidation, for a maximum of eight cycles. A total of 25 patients (20 ALL and 5 AML) were enrolled in five cohorts. An MTD was not reached. The RP2Ds of clofarabine, cyclophosphamide and etoposide were 40, 440 and 100 mg/m 2 /day, respectively. Complete remission (CR) was achieved in 10 patients (ALL: nine; AML: one), and CR without platelet recovery in six patients (ALL: two; AML: four) for an overall response rate of 64% (ALL: 55%; AML: 100%). Of the 16 responders, 9 patients proceeded to hematopoietic stem cell transplantation. In conclusion, the combination of clofarabine, etoposide and cyclophosphamide was well tolerated and effective in pediatric patients with relapsed/refractory leukemia. Of note, the phase II portion of the trial was amended after the occurrence of unexpected hepatotoxicity. The ongoing phase II study will evaluate the efficacy and safety of this regimen in ALL patients.
Introduction
Acute leukemia is the most common cause of malignancy in children less than 18 years of age. 1 Advances in effective therapy have improved outcomes in recent years such that 5-year survival rates now approach 85% for acute lymphoblastic leukemia (ALL) and 50-60% for acute myelogenous leukemia (AML). 2 However, the prognosis remains poor for children who experience relapses or who are refractory to front-line therapy. 3 Thus, new therapeutic approaches are urgently needed in this patient population.
Clofarabine (2-chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine) is a second-generation deoxyadenosine analog synthesized to overcome the limitations, but retain the favorable properties of fludarabine and cladribine. 4 In both phase I and phase II studies, single-agent clofarabine has been shown to be effective in inducing remission at well-tolerated doses in pediatric patients with multiple relapsed or refractory leukemia. 5, 6 In a phase II study of clofarabine in pediatric patients with multiple relapsed or refractory ALL, 20% of patients achieved a remission (complete remission (CR) þ CR in the absence of total platelet recovery (CRp)) and remissions were also observed in patients who were refractory to standard salvage treatments. 6 Given the encouraging single-agent activity and acceptable safety profile of clofarabine, a mechanism-based combination with cyclophosphamide and etoposide was evaluated. In vitro biochemical synergy has been shown between the triphosphate form of clofarabine, which inhibits DNA polymerases and ribonucleotide reductase, and the alkylating agent cyclophosphamide. [7] [8] [9] [10] [11] Cells pretreated with clofarabine impeded repair of cyclophosphamide-induced DNA damage, which in turn resulted in a more than additive apoptotic cell death. 12 Furthermore, in clinical studies, etoposide, another DNA-damaging agent, has been shown to have anti-leukemic activity when used in combination with cyclophosphamide and has been incorporated in many protocols for high risk or relapsed ALL. 13, 14 We initiated this phase I study to determine the maximum tolerated dose (MTD) of clofarabine when used in combination with etoposide and cyclophosphamide, and to characterize the potential activity and safety of this regimen to treat children with relapsed acute leukemia. 15, 16 The phase II portion of the study is currently ongoing. The results of the completed phase I study are reported herein.
Patients and methods

Study group
Patients between 1 and 21 years old with a body weight of 410 kg and a diagnosis of relapsed or refractory ALL or AML were eligible. Diagnostic categories were as follows: (1) ALL with 425% bone marrow (BM) blasts and no more than three prior induction regimens and (2) AML with X5% BM blasts and no more than two prior induction regimens. Other eligibility criteria included no more than one prior hematopoietic stem cell transplant (HSCT); resolution of acute toxic effects from prior chemotherapy; Karnofsky Performance Status of X50 (410 years old) or Lansky Performance Status of X50 (p10 years old); serum bilirubin p1.5 Â ULN (Upper Limit of Normal) for age, alanine aminotransferase (AST) and aspartate aminotransferase p2.5 Â ULN, serum creatinine o2 Â ULN, serum amylase and serum lipase p1.5 Â ULN for age, and echocardiogram with shortening fraction X28% or ejection fraction X50%; and the absence of active, uncontrolled systemic infection, severe concurrent disease or central nervous system involvement defined as X5 leukocytes/ml of CSF with blast cells (CNS-3). Patients with Burkitt's leukemia or acute promyelocytic leukemia, and patients with transplantation within 4 months or active graft versus host disease were also excluded. Approval for the study was granted from the Institutional Review Boards. Informed consent was obtained from parents or guardians and assent was obtained from patients X7 years of age. The study was conducted in accordance with the basic principles of the Declaration of Helsinki.
Treatment plan
A standard 3 þ 3 design 17 was to be followed. Clofarabine was administered as a 2-h intravenous infusion for five consecutive days at an initial dose of 20 mg/m 2 /day. Etoposide was administered as a 2-h intravenous infusion at an initial dose of 75 mg/m 2 /day, daily for 5 days. Cyclophosphamide was administered as an initial dose of 340 mg/m 2 /day, daily for 5 days, through a 30-60 min intravenous infusion. After etoposide and cyclophosphamide were escalated to their target doses, the dose of clofarabine was increased in subsequent cohorts to its target dose (Table 1) .
After an induction cycle, subsequent courses were determined by a BM aspirate and/or biopsy performed between days 14 and 21, and repeated weekly thereafter until either remission or persistent leukemia was documented. Patients with X5% BM blasts could receive a second cycle of induction and, if not able to achieve a response, were discontinued from further study therapy. Consolidation cycles were administered for four consecutive days with the same daily doses given during induction. Patients could receive a maximum of eight total cycles of treatment.
Treatment with intrathecal prophylaxis was optional for patients with AML but was required for patients with ALL (cytarabine before the first induction and methotrexate in subsequent cycles). Granulocyte-colony stimulating factor (5-10 mg/kg) was initiated on day 6 of induction/reinduction (day 5 of consolidation) and administered until recovery of ANC to 40.75 Â 10 9 per liter. Infection prophylaxis was recommended as per institutional guidelines.
Response and toxicity criteria
Response to treatment was determined by the investigator. A patient's best response after induction or reinduction was used to determine overall remission (OR) (CR þ CRp). CR was defined as M1 marrow (o5% blasts) and recovery of peripheral counts (platelets X75 Â 10 9 per liter and ANC X0.75 Â 10 9 per liter for ALL; platelets X100 Â 10 9 per liter and ANC X1.0 Â 10 9 per liter for AML). CR in the absence of total platelet recovery (CRp) was defined as CR except for recovery of platelet count to X20 Â 10 9 per liter but o100 Â 10 9 per liter. Partial remission was defined as complete disappearance of circulating blasts; appearance of normal hematopoietic progenitor cells; and either a BM with X5 and p25% blasts with recovery of peripheral counts or a BM with o5% blasts that did not qualify for CR or CRp. Stable disease was defined as the patient failing to qualify for either CR, CRp, partial remission or progressive disease.
Adverse events (AEs) were evaluated using National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE v3.0). Dose-limiting toxicities (DLTs) were assessed only during Cycle 1. Dose delays or reduction of study drug doses were not required for hematological toxicity or infection occurring during induction cycles. Grade 2 or greater nonhematological and non-infectious toxicities (excluding rash, anorexia, nausea, vomiting, diarrhea, mucositis, and transient elevations in liver transaminases or alkaline phosphatase) occurring during drug administration required suspension of study drugs until recovery to baseline before resuming treatment.
Prolonged hematopoietic recovery or BM aplasia (442 days) during Cycle 1, in addition to grade 4 neutropenia or grade 4 thrombocytopenia lasting 428 days during any cycle, necessitated a 20% dose reduction of study drugs in subsequent cycles. Delay of consolidation cycle initiation was required if a clinically significant infection was present; treatment could resume at full dose when the infection was under control. For grade 3 drug-related, non-infectious events that resolved by day 84 from day 1 of the cycle, study treatment was to be reinitiated at a 25% dose reduction for all subsequent cycles. If the event did not resolve by day 84, further treatment cycles were not administered. Exceptions to this requirement included grade 3 or greater anorexia, transient isolated elevations in transaminases or alkaline phosphatase, nausea, vomiting, diarrhea or mucositis. For grade 4, drug-related, non-infectious toxicities, further study treatment was not to be administered except under extraordinary circumstances.
Statistical methods
This was an open-label, multi-center phase I/II study conducted at 12 US sites. The primary objectives in phase I were to determine the MTD, DLT and the recommended phase 2 dose (RP2D) of clofarabine when used in combination with etoposide and cyclophosphamide. Secondary objectives were to determine the safety and tolerability of this combination, estimating the OR rate, and documenting the duration of remission (DOR) and overall survival (OS). Summary statistics were used to describe response rates. Kaplan-Meier estimates were used to describe time-to-event outcomes such as DOR and OS. DOR was calculated censoring patients known to be in remission at the time of last known follow-up, and separately with censoring at the time of alternative therapy or HSCT.
Safety was monitored by an independent DSMB (Data Safety Monitoring Board).
Results
Patients and treatment
The first patient began treatment on 11 March 2006, and the date of data cutoff was 31 October 2008. All patients who received any amount of study drugs were included in the Table 1 Dose escalation scheme Table 2 . There were 20 (80%) patients with ALL and 5 (20%) patients with AML. Most patients were heavily pretreated with a median of two prior therapies for ALL patients and one prior therapy for AML patients. One patient with ALL and three patients with AML had prior HSCT. Seven patients (five ALL and two AML) were refractory to their immediately preceding chemotherapy regimen.
The majority of patients received one (n ¼ 9) or two (n ¼ 9) cycles of study therapy. One patient in Cohort 3 received eight cycles of treatment, the maximum permitted by the protocol. The time between cycles ranged from 23 to 75 days for all dose levels (median: 34 days).
Determination of MTD and RP2D
There were no DLTs in the first three cohorts. In Cohort 4, a DLT of grade 3 lipase elevation, grade 3 abdominal pain and hepatomegaly were observed in one patient. Venoocclusive disease could not be excluded in this patient whose symptoms resolved without sequelae. Another patient in this cohort developed grade 2 pancreatitis and grade 3 lipase elevation; however, these did not meet DLT criteria. Consequently, this cohort was expanded to 10 patients and no further DLTs were observed. In Cohort 5, one patient experienced a DLT of prolonged BM aplasia (beyond day 42). In total, five additional patients were enrolled in Cohort 5 and no further DLTs were noted. Therefore, MTD was not reached and the RP2Ds were determined to be clofarabine 40 mg/m 2 /day, cyclophosphamide 440 mg/m 2 /day and etoposide 100 mg/m 2 /day.
Toxicity
Treatment-related AEs observed in 420% of patients are listed in Table 3 . Febrile neutropenia was reported in 64% of patients. Documented infections occurred in 72% of patients; however, no individual infection had an incidence of 420%. Of the 18 patients with reported bacterial, fungal or viral infections, 16 were grade 3 and two were grade 4. Although not reported as AEs, the most frequently occurring grade 3 or 4 elevated serum chemistry abnormalities (X10%) included increased aspartate aminotransferase and alanine aminotransferase (38%) and hyperglycemia (25%). No grade 3 or 4 elevations in bilirubin were documented. A total of four patients had a dose reduction (n ¼ 2) or interruption (n ¼ 2) in the administration of clofarabine. Reasons for clofarabine dose modifications included increased lipase, hypersensitivity and vomiting. In addition, one patient required a dose interruption in both cyclophosphamide and etoposide due to an allergic reaction, and three patients had a dose delay or interruption in etoposide only (two due to hypotension and one due to rash). Three deaths due to AEs were reported, including two deaths attributed to study drugs. One patient died of Micrococcus meningitis 52 days after completion of the induction course, and another patient died of intraventricular hemorrhage due to thrombocytopenia and disseminated intravascular coagulation 24 days after the third cycle of study drugs. 
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The third patient, who had undergone HSCT after study treatment, died of multi-organ failure assessed as unrelated to study drugs 100 days after the last dose.
Treatment outcome
The OR rate was 64% (ALL: 55%; AML: 100%) ( Table 4 ). A total of 10 patients (nine ALL, one AML) achieved CR and 6 patients (two ALL, four AML) achieved CRp. The response rate was 69% (nine CR) in the 13 patients with B-cell precursor ALL, and 20% (one CRp) in the 5 patients with T-cell ALL. Additionally, four patients had stable disease, four patients had progressive disease and one patient was not evaluable (this patient had prolonged marrow aplasia and died of Micrococcus meningitis before count recovery). A total of 14 patients achieved remission after the first cycle, although two patients achieved CR/CRp after Cycle 2. One patient with ALL achieved CR after one cycle and completed eight cycles of study therapy, with a DOR of 61.4 weeks.
Responses were seen among patients in all dose cohorts: in Cohort 1 (n ¼ 3), there was one CR and one CRp; in Cohort 2 (n ¼ 3), there were two CRs; in Cohort 3 (n ¼ 3), there was one CR and two CRps; in Cohort 4 (n ¼ 10), there were three CRs and three CRps and in Cohort 5 (n ¼ 6), there were three CRs. Notably, of the seven patients who were refractory to their immediately preceding chemotherapy regimen, three achieved CR or CRp. Characteristics of the responding patients are shown in Tables 5A and 5B . The 16 responders were followed for a median of 37.0 weeks. The median DOR at the last known date of follow-up was 18.2 weeks (27.0 weeks for the 10 patients with CR and 15.3 weeks for the 6 patients with CRp) ( Table 4 ). The median DOR was 22.6 weeks (range, 6.6 to 105.1 þ weeks) for the 11 ALL responders and 15.6 weeks (range, 7.3 to 61.0 þ weeks) for the 5 AML responders. In total, 9 (56%) of the 16 responders proceeded to HSCT. Median DOR censored at the date of HSCT is shown in Table 4 .
Of note, two patients who proceeded to HSCT post study died after developing venoocclusive disease during or shortly after the administration of the transplant conditioning regimens. Both patients had AML with a history of prior allogeneic HSCT occurring 18-24 months before their second HSCT.
The median survival for the 16 responders was 37.0 weeks (range, 13.7 to 109.0 þ weeks) with a median of 40.5 weeks for the 10 patients with CR and 29.5 weeks for the 6 patients with CRp (Table 4) . For ALL patients (n ¼ 11) and AML patients (n ¼ 5) in remission, median OS was 42.9 weeks and 23.1 weeks, respectively. Patients with stable disease (n ¼ 4) had a median OS of 19.3 weeks compared with 11.7 weeks for patients (n ¼ 5) with progressive disease/not evaluable.
Discussion
Single-agent clofarabine has significant anti-leukemic activity in childhood acute leukemia. 5, 6 In this phase I study, we sought to determine the MTD of clofarabine when used in combination with cyclophosphamide and etoposide. However, as the doses evaluated in the target dose cohort (Cohort 5) were found to be tolerable and an MTD was not reached, the RP2Ds of clofarabine, cyclophosphamide and etoposide were determined to be 40, 440 and 100 mg/m 2 /day, respectively, each given for five consecutive days.
We found this combination regimen was generally well tolerated. A minority of patients required dose modifications in Table 4 Treatment outcome (N ¼
25)
Response category Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CR, complete remission; CRp, complete remission in the absence of total platelet recovery; DOR, duration of remission; HSCT, hematopoietic stem cell transplant; OS, overall survival; PR, partial remission; SD, stable disease, the patient fails to qualify for either CR, CRp, PR or PD; PD, progressive Disease, an increase of at least 25% of the absolute number of BM or circulating leukemic blasts, development of extramedullary disease, or other laboratory or clinical evidence of progression; NE, not evaluable.
a Patient died before bone marrow (BM) recovery. Note: +, censored observation.
Clofarabine combination in relapsed acute leukemia N Hijiya et al subsequent cycles. The most common treatment-related AEs (nausea, vomiting, febrile neutropenia and infection) were as anticipated in this patient population. Similar to single-agent clofarabine studies, no drug-related central nervous system toxicities were observed, whereas significant neurotoxicity has been reported with other deoxyadenosine nucleoside analogs. 18, 19 Hematological toxicity was reasonable for this patient population. One patient had a duration of 75 days between cycles; this delay occurred at the initiation of Cycle 3 and was due to prolonged thrombocytopenia. Owing to this patient's prolonged thrombocytopenia, an exception was made so that this patient could proceed with Cycle 3 treatment. It is important to note, however, that the majority of patients received therapy without delays (median of 34 days between cycles).
In this study, we report an OR rate of 64%. Responses were achieved in 11/20 (55%) patients with ALL and 5/5 (100%) patients with AML. These findings are highly encouraging given that the historic CR rate for ALL in second or third relapse is p40%.
3 In addition, the OR rate of 55% observed in patients with ALL (nine CRs þ two CRps) was higher than the OR rate of 20% (seven CRs þ five CRps) in the pivotal phase II study of single-agent clofarabine in 61 pediatric patients in a similar patient population, 6 supporting the benefit of clofarabine combination therapy with DNA-damaging agents. 12 All five patients with AML, most who were in first relapse, achieved a response (one CR þ four CRp). This is also very encouraging given the historical CR rate of approximately 36-75% in patients with AML in first relapse. 20 This highly promising response observed in this small population of AML patients warrants further study. On the basis of the phase I findings reported, a phase II evaluation of this combination regimen is currently underway. The phase II portion of the study is a single-arm open-label trial with eligibility restricted to patients with ALL who have received no more than three earlier induction regimens. In the first eight patients enrolled in the phase II portion, four patients developed severe hepatotoxicity (three venoocclusive disease; one hyperbilirubinemia). 16 Three of these patients had concurrent severe infections. In addition, three patients had undergone prior HSCT within the year preceding study entry. Therefore, the study was amended to exclude patients with prior HSCT, a history of viral hepatitis and/or cirrhosis or elevated conjugated bilirubin levels at study entry; observation periods and safety reviews by an external DSMB also comprised the amended phase II study design. Seven patients have been enrolled in the amended study thus far and none have experienced severe hepatotoxicity. The etiology of the severe liver toxicity is likely multi-factorial, possibly related to the presence of concurrent infections and/or previous HSCT.
However, given that reversible hepatotoxicity is a relatively common occurrence with clofarabine and severe hepatotoxicity can occur in some cases, close monitoring of liver function is recommended during and after clofarabine therapy. During treatment, concurrent use of other medications associated with hepatotoxicity should be avoided, if possible. Clofarabine should be discontinued if Xgrade 3 hyperbilirubinemia develops, and This patient's induction regimen was altered after 3 weeks due to lack of response. He achieved first CR after his second regimen. Clofarabine combination in relapsed acute leukemia N Hijiya et al once the patient has recovered and if therapy is resumed, a 25% reduction in dose is recommended. In summary, this study supports the rationale for the use of clofarabine combined with cyclophosphamide and etoposide for heavily pretreated pediatric patients with relapsed and refractory ALL or AML. The ongoing phase II portion of this study will help further define the role of this promising regimen in patients with ALL. Further evaluation of this regimen in pediatric patients is also planned in a pilot study in ALL patients in first relapse, a phase II study of patients with relapsed/refractory AML and in a front-line phase III study in patients with very high risk ALL.
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